Should I buy or sell Aurinia Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks .

What is Aurinia Pharmaceuticals' stock price target for 2024?

2 brokers have issued 12-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 58.7% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts .

How have AUPH shares performed in 2023?

Aurinia Pharmaceuticals' stock was trading at $4.32 on January 1st, 2023. Since then, AUPH stock has increased by 104.2% and is now trading at $8.82. View the best growth stocks for 2023 here .

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our AUPH earnings forecast .

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. The biotechnology company earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 19.54% and a negative net margin of 48.59%.

What ETFs hold Aurinia Pharmaceuticals' stock?

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) . ALPS Medical Breakthroughs ETF (SBIO) .

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Micron Technology (MU) , Sorrento Therapeutics (SRNE) , Cara Therapeutics (CARA) , Exelixis (EXEL) , AbbVie (ABBV) , Amarin (AMRN) and Array Technologies (ARRY) .

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.21%), Northern Trust Corp (0.73%), Group One Trading L.P. (0.00%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.27%) and Stifel Financial Corp (0.25%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage , Joseph M Miller , Joseph P Hagan, Matthew Maxwell Donley , Michael Robert Martin , Neil Solomons , Peter Greenleaf , Robert Bindert Huizinga and Stephen P Robertson. View institutional ownership trends .

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Aurinia Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AUPH)

$8.82

-0.24 (-2.65%)

(As of 12/4/2023 ET)

Compare

Today's Range: $8.68
▼
$9.13
50-Day Range: $7.13
▼
$9.24
52-Week Range: $4.07
▼
$12.43

Volume: 2.40 million shs
Average Volume: 2.59 million shs
Market Capitalization: $1.27 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Aurinia Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 58.7% Upside
$14.00 Price Target
Short Interest: Bearish
11.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

716th out of 952 stocks

Pharmaceutical Preparations Industry

336th out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Aurinia Pharmaceuticals has a forecasted upside of 58.7% from its current price of $8.82.
Amount of Analyst Coverage
Aurinia Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.97% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Aurinia Pharmaceuticals has recently decreased by 0.52%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aurinia Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Aurinia Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AUPH.

3.2

News and Social Media Coverage

News Sentiment
Aurinia Pharmaceuticals has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 24 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
5 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Aurinia Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 39.64% of the stock of Aurinia Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.51) to ($0.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aurinia Pharmaceuticals is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aurinia Pharmaceuticals is -16.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aurinia Pharmaceuticals has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

AUPH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AUPH Stock News Headlines

December 2, 2023 | finance.yahoo.com

Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past year

November 23, 2023 | finance.yahoo.com

Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 22, 2023 | seekingalpha.com

Aurinia Pharma goes negative even amid takeover speculation

November 21, 2023 | msn.com

Aurinia Pharma jumps amid takeover speculation

November 13, 2023 | businesswire.com

Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS ® (Voclosporin) in Japan

November 13, 2023 | msn.com

Aurinia partner files for Japan approval of lupus nephritis drug

November 7, 2023 | finance.yahoo.com

Wall Street Analysts See a 59.35% Upside in Aurinia (AUPH): Can the Stock Really Move This High?

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

November 7, 2023 | finance.yahoo.com

Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023

November 3, 2023 | msn.com

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

November 3, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript

November 3, 2023 | finance.yahoo.com

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

November 2, 2023 | finance.yahoo.com

Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis

October 26, 2023 | finance.yahoo.com

Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis

October 19, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023

October 16, 2023 | finance.yahoo.com

Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls

October 13, 2023 | finance.yahoo.com

Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)

October 9, 2023 | finance.yahoo.com

J&J (JNJ) Seeks EU Nod for Rybrevant for First-Line NSCLC

October 3, 2023 | finance.yahoo.com

Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection

September 27, 2023 | finance.yahoo.com

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?

September 27, 2023 | seekingalpha.com

Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade)

September 21, 2023 | finance.yahoo.com

Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

September 18, 2023 | msn.com

Why Aurinia Pharmaceuticals Stock Is Slumping Today

September 18, 2023 | finance.yahoo.com

5 Stocks to Buy as Drug Industry Displays Strong Fundamentals

September 11, 2023 | finance.yahoo.com

Here's Why We're Not At All Concerned With Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn Situation

September 6, 2023 | finance.yahoo.com

Wall Street Analysts Think Aurinia (AUPH) Could Surge 42.86%: Read This Before Placing a Bet

See More Headlines

Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AUPH
CUSIP: N/A
CIK: 1600620
Web: www.auriniapharma.com
Phone: 250-708-4272
Fax: 250-744-2498
Employees: 300
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $15.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +58.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-108,180,000.00
Net Margins: -48.59%
Pretax Margin: -48.00%
Return on Equity: -19.54%
Return on Assets: -15.24%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 5.77
Quick Ratio: 5.33

Sales & Book Value

Annual Sales: $134.03 million
Price / Sales: 9.45
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.85 per share
Price / Book: 3.09

Miscellaneous

Outstanding Shares: 143,610,000
Free Float: 137,433,000
Market Cap: $1.27 billion
Optionable: Optionable
Beta: 1.25

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Peter S. Greenleaf M.B.A. (Age 53)
President, CEO & Director
Comp: $1.34M
Mr. Joseph M. Miller CPA (Age 49)
Chief Financial Officer
Comp: $791.92k
Mr. Matthew Maxwell Donley M.B.A. (Age 54)
Executive Vice President of Operations & Strategy
Comp: $811.82k
Mr. Stephen P. Robertson (Age 41)
Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer
Comp: $739.68k
Dr. Volker Knappertz D.Sc. (Age 58)
M.D., Executive Vice President of Research & Development
Comp: $742.85k
Mr. James Archie Harrell Jr. (Age 53)
Head of Investor Relations
Mr. Fran Lynch
Vice President of Sales
Mr. Michael R. Martin (Age 51)
Chief Business Officer
Comp: $350.57k
Ms. Sue Evans
Senior Vice President of Global Regulatory Affairs
Mr. Scott Habig (Age 63)
Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AUPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.
What is Aurinia Pharmaceuticals' stock price target for 2024?: 2 brokers have issued 12-month price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $13.00 to $15.00. On average, they expect the company's share price to reach $14.00 in the next year. This suggests a possible upside of 58.7% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.
How have AUPH shares performed in 2023?: Aurinia Pharmaceuticals' stock was trading at $4.32 on January 1st, 2023. Since then, AUPH stock has increased by 104.2% and is now trading at $8.82.
View the best growth stocks for 2023 here.
When is Aurinia Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our AUPH earnings forecast.
How were Aurinia Pharmaceuticals' earnings last quarter?: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. The biotechnology company earned $54.52 million during the quarter, compared to the consensus estimate of $38.41 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 19.54% and a negative net margin of 48.59%.

What ETFs hold Aurinia Pharmaceuticals' stock?: ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).
What other stocks do shareholders of Aurinia Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).
Who are Aurinia Pharmaceuticals' major shareholders?: Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (4.21%), Northern Trust Corp (0.73%), Group One Trading L.P. (0.00%), Bank of New York Mellon Corp (0.28%), Charles Schwab Investment Management Inc. (0.27%) and Stifel Financial Corp (0.25%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.
How do I buy shares of Aurinia Pharmaceuticals?: Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AUPH) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial